DBVT News and Press, DBV Technologies S.A. From 09/05/25

2025-09-05 16:59:24 ET More on DBV Technologies Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the full article on Seeking Alpha For further details...

Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, ...

Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27 th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clini...

2025-08-14 16:15:00 ET Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease ...

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext ...

2025-07-29 16:52:49 ET More on DBV Technologies DBV Technologies: A Great Time To Sell Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the full art...

Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmace...

Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, tod...

AstraZeneca PLC (AZN) is expected to report $1.09 for Q2 2025 Commvault Systems Inc. (CVLT) is expected to report $0.47 for Q1 2026 Ares Capital Corporation (ARCC) is expected to report $0.51 for Q2 2025 Northwest Bancshares Inc. (NWBI) is expected to report $0.29 for Q2 2025 Repl...

DBV Technologies S.A. (DBVT) is expected to report $-0.2 for Q2 2025